Cover Image
市場調查報告書

肝性腦病變:開發中產品分析

Hepatic Encephalopathy - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213083
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
肝性腦病變:開發中產品分析 Hepatic Encephalopathy - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 60 Pages
簡介

所謂肝性腦病變是指肝臟無法消除血液中有害物質,造成腦功能隨之惡化的疾病。主要的症狀為喪失方向感、嗜睡、意識障礙、睡眠模式的變化、語言障礙、興奮、(在某些情況下)中風等。主要的易罹病素質包含腸胃出血和蛋白質攝取量的增加、高氮血症的腎功能不全、(伴隨氮攝取量增加)便秘、醫藥品(特別是鎮靜劑、利尿劑)、低氧症等。

本報告提供全球各國治療肝性腦病變所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

肝性腦病變概要

治療藥的開發

  • 肝性腦病變開發中產品:概要
  • 肝性腦病變開發中產品:比較分析

各企業開發中的肝性腦病變治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

肝性腦病變治療藥:開發中的產品一覽(各企業)

肝性腦病變治療藥的開發企業

  • Alfa Wassermann S.p.A
  • Cosmo Pharmaceuticals S.p.A
  • Horizon Pharma Plc
  • KannaLife Sciences, Inc.
  • Ocera Therapeutics, Inc.
  • Rebiotix Inc.
  • Spherium Biomed S.L.
  • Umecrine Cognition AB

肝性腦病變:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝性腦病變治療藥:開發暫停的產品

肝性腦病變相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9529IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2017, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 5 and 1 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatic Encephalopathy - Overview
    • Hepatic Encephalopathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hepatic Encephalopathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatic Encephalopathy - Companies Involved in Therapeutics Development
    • Cosmo Pharmaceuticals NV
    • Ocera Therapeutics Inc
    • Rebiotix Inc
    • Spherium Biomed SL
    • Synlogic Inc
    • Umecrine Cognition AB
    • Versantis AG
  • Hepatic Encephalopathy - Drug Profiles
    • GR-3027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KLS-13019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ornithine phenylacetate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBX-2477 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBX-2660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifamycin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYNB-1020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THDP-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatic Encephalopathy - Dormant Projects
  • Hepatic Encephalopathy - Discontinued Products
  • Hepatic Encephalopathy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
      • May 26, 2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease
      • Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
      • Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
      • Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
      • Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
      • Nov 10, 2016: Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
      • Nov 02, 2016: Ocera Therapeutics: Update on OCR-002
      • Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
      • Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
      • Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
      • Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
      • Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
      • Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
      • Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hepatic Encephalopathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, H2 2017
  • Hepatic Encephalopathy - Pipeline by Ocera Therapeutics Inc, H2 2017
  • Hepatic Encephalopathy - Pipeline by Rebiotix Inc, H2 2017
  • Hepatic Encephalopathy - Pipeline by Spherium Biomed SL, H2 2017
  • Hepatic Encephalopathy - Pipeline by Synlogic Inc, H2 2017
  • Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2017
  • Hepatic Encephalopathy - Pipeline by Versantis AG, H2 2017
  • Hepatic Encephalopathy - Dormant Projects, H2 2017
  • Hepatic Encephalopathy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Hepatic Encephalopathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top